Paradoxical metastatic progression following 3months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer, "Beyond the Abstract," by James W. Denham, MD, FRANZCR

BERKELEY, CA (UroToday.com) - This paper raises the very unpleasant possibility that testosterone recovery can stimulate the growth of metastatic tumour deposits that have not been eradicated by prior adjuvant androgen suppression therapy in men treated curatively for locally advanced cancers who have apparently negative scans for metastases. Three-month durations of androgen suppression should be used cautiously in the adjuvant setting.

The reviewers of this paper liked the short review provided in the electronic appendix...please take a look at it.

Written by:
James W. Denham, MD, FRANZCR as part of Beyond the Abstract on UroToday.com. This initiative offers a method of publishing for the professional urology community. Authors are given an opportunity to expand on the circumstances, limitations etc... of their research by referencing the published abstract.

Director
Prostate Cancer Trials Group
University of Newcastle
University Drive
Callaghan NSW 2308
Australia
Email:

Paradoxical metastatic progression following 3months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer - Abstract

More Information about Beyond the Abstract